In terms of antiglycemic medications prescribed for participants with T2DM, metformin was the most common drug prescribed (n = 31, 55.3%), followed by insulin (n = 24, 42.8%), and then SGLT2 inhibitors (n = 20, 35.7%). Here, SLC5A2 is linked to type 2 diabetes mellitus.